NEOS Investment Management LLC lifted its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 43.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 19,040 shares of the biotechnology company's stock after acquiring an additional 5,736 shares during the quarter. NEOS Investment Management LLC's holdings in Ascendis Pharma A/S were worth $2,621,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Rice Hall James & Associates LLC increased its stake in shares of Ascendis Pharma A/S by 2.0% during the fourth quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company's stock valued at $22,562,000 after buying an additional 3,274 shares during the period. Nomura Asset Management Co. Ltd. boosted its position in shares of Ascendis Pharma A/S by 42.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company's stock worth $2,688,000 after purchasing an additional 5,371 shares in the last quarter. Maven Securities LTD bought a new position in Ascendis Pharma A/S during the 3rd quarter valued at approximately $7,466,000. Exome Asset Management LLC raised its stake in Ascendis Pharma A/S by 119.2% during the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company's stock valued at $6,547,000 after buying an additional 23,849 shares during the last quarter. Finally, abrdn plc boosted its holdings in Ascendis Pharma A/S by 18.3% in the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock worth $25,769,000 after acquiring an additional 28,967 shares in the last quarter.
Ascendis Pharma A/S Trading Up 1.3 %
ASND stock traded up $1.95 during midday trading on Wednesday, reaching $153.38. The stock had a trading volume of 179,773 shares, compared to its average volume of 466,291. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $169.37. The company's fifty day simple moving average is $145.13 and its 200 day simple moving average is $137.86. The company has a market cap of $9.31 billion, a price-to-earnings ratio of -21.55 and a beta of 0.61.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.64. Sell-side analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. Evercore ISI raised their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 18th. The Goldman Sachs Group upped their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald boosted their price objective on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $204.64.
Get Our Latest Research Report on Ascendis Pharma A/S
Ascendis Pharma A/S Company Profile
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Articles
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
